middle.news
How Safe Is Noxopharm’s SOF-SKN™? Second Dose Cohort Clears Key Hurdle
8:44am on Monday 11th of August, 2025 AEST
•
Biotechnology
Read Story
How Safe Is Noxopharm’s SOF-SKN™? Second Dose Cohort Clears Key Hurdle
8:44am on Monday 11th of August, 2025 AEST
Key Points
Second dose cohort of SOF-SKN™ completed with no safety concerns
Trial progressing to third cohort with increased dosage
HERACLES trial focuses on safety, tolerability, and dose finding
SOF-SKN™ targets autoimmune diseases, initially cutaneous lupus erythematosus
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NOX
OPEN ARTICLE